Floxuridine

This page contains recent news articles, when available, and an overview of Floxuridine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Floxuridine (when available)

Pharmacology and use:
Floxuridine is a pyrimidine analog that acts as an inhibitor of the S-phase of cell division. This selectively kills rapidly dividing cells. Floxuridine is an anti-metabolite. Anti-metabolites masquerade as pyramidine-like molecules which prevents normal pyrimidines from being incorporated into DNA during the S phase of the cell cycle. Flurouracil (the end-product of catabolism of floxuridine) blacks an enzyme which converts cytosine nucleosides into the deoxy derivative. In addition, DNA synthesis is further inhibited because fluoruracil blocks the incorporation of the thymdine nucleotide into the DNA strand. For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means.

Mechanism Of Action:
Floxuridine is rapidly catabolized to 5-fluorouracil which is the active form of the drug. Fluorouracil inhibits thymydilate synthase leading to inhibition of DNA synthesis, RNA synthesis and cell death.

News Articles on Floxuridine

Floxuridine (Systemic).  -  Feb 1, 2006
Floxuridine ( flox-YOOR-i-deen) belongs to the group of medicines known as antimetabolites. It is used to treat some kinds of cancer. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

FLOXURIDINE (Injection route) - flox-YOOR-i-deen.(Drug overview)  -  May 1, 2007
It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

Radiation Therapy Improves Outcome of Unresectable Liver Cancer  -  Dec 5, 2005
NEW YORK DEC 05, 2005 (Reuters Health) - Adding high-dose conformal radiation therapy (RT) to intra-arterial floxuridine improves outcomes in patients with ... Cancerpage.com

Chemoradiation May Extend Lives of Patients With Inoperable Liver …  -  Nov 29, 2005
In addition, chemotherapy delivered via the hepatic artery, in this case with the agent FUDR (floxuridine), carries high doses directly to the tumor, ... MedPage Today

Celator: Combining chemo drugs for fun and profit  -  Aug 2, 2007
Celator's lead candidate, CPX-1, is a combination of irinotecan and floxuridine at the cleverly derived molar ratio of, um, one to one. ... VentureBeat

irinotecan + floxuridine Celator phase change II, USA, Canada...  -  Nov 13, 2006
Celator is conducting a phase II trial of CPX 1 in patients with colorectal cancer in the USA and Canada. The non-randomized, multicenter, open-label trial, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones

Illinois Administrative Code - 77 Ill. Adm. Code 790.3920 FLOXURIDINE...  -  Aug 10, 2005
77 Ill. Adm. Code 790.3920 FLOXURIDINE (Repealed) Repealed. (Source: Repealed at 17 Ill. Reg. 15916, effective September 20, 1993) ... Pay-Per-View - Illinois Administrative Code - Loislaw

Celator Pharmaceuticals raises Series C financing of over USD 22.5m.  -  Jul 29, 2008
In addition, positive Phase 2 clinical study results were reported for CPX-1 (a liposomal formulation of irinotecan:floxuridine) in patients with advanced ... $9.94 - M2 Europharma - Alacra Store

Loislaw Federal District Court Opinions - BOLDON v. HUMANA INS. CO. (...  -  Dec 13, 2006
Two of the patients receiving [floxuridine] plus [microspheres] had a complete ... By comparison, one patient receiving [floxuridine] alone achieved a ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw

Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer ...  -  Jun 4, 2007
CPX-1 is a combination therapy including irinotecan HCI and floxuridine, two approved and well known drug agents to treat cancer. The formulation of CPX-1 ... Free with registration - PR Newswire - AccessMyLibrary.com

Press Release: Celator(R) Pharmaceuticals to Present at Piper Jaffray...  -  Nov 25, 2008
The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; ... Pay-Per-View - PR Newswire - HighBeam Research

Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal...  -  Mar 23, 2007
The chronopharmacokinetics of FU has stimulated clinical trials of chronomodulated delivery schedules for floxuridine 6 and FU infusions 7 , suggesting that ... Nature.com

Celator Pharmaceuticals Raises Series C Financing in Excess of .5 …  -  Jul 28, 2008
In addition, positive Phase 2 clinical study results were reported for CPX-1 (a liposomal formulation of irinotecan:floxuridine) in patients with advanced ... RedOrbit

Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX...  -  Jun 3, 2008
CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a ... RedOrbit

Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson As ...  -  May 9, 2008
Results from a Phase 2 study of CPX-1 (a liposomal formulation of irinotecan:floxuridine) in patients with advanced colorectal cancer will be reported later ... RedOrbit

Press Release: Celator Pharmaceuticals Presents Positive Results From...  -  Jun 5, 2006
CPX-1, a fixed-ratio formulation of irinotecan and floxuridine, was developed using ... Read all of this article with a FREE trial ... Pay-Per-View - PR Newswire - HighBeam Research

What is the standard chemotherapy for colorectal cancer patients with...  -  Jun 30, 2008
...(2003) Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment ... Nature.com

Tumor assault extends liver cancer survival  -  Dec 1, 2005
In the study, patients received radiation twice daily for two weeks, along with a continuous infusion of the chemotherapy drug floxuridine. ... Cancerfacts.com

Radiation Treatment Prolonged Liver Cancer Patients' Lives  -  Nov 22, 2005
In the study, patients received radiation twice daily for two weeks, along with a continuous infusion of the chemotherapy drug floxuridine. ... newswise.com

Celator Pharmaceuticals Announces Positive European Patent Decision …  -  Jul 17, 2006
Celator Pharmaceuticals also recently announced positive results from a Phase 1 study for CPX-1, a fixed-ratio formulation of irinotecan and floxuridine ... Genetic Engineering News - Genetic Engineering News (press release)

Hepatic Arterial Infusion Improves Survival in Metastatic Colorectal ...  -  Mar 16, 2006
Dr. Kemeny and colleagues compared hepatic arterial infusion treatment with floxuridine, leucovorin, and dexamethasone and with fluorouracil and leucovorin ... Cancerpage.com

Press Release: Celator(R) Pharmaceuticals Study Shows Anti-Tumor …  -  Jun 4, 2007
...results from its Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), Liposome Injection in patients with heavily pre-treated, advanced solid tumors. ... Pay-Per-View - PR Newswire - HighBeam Research

New Guidelines Prefer Clinical Trial for Advanced Kidney Cancer …  -  Mar 10, 2008
There was disagreement among the guideline-committee members as to the usefulness of chemotherapeutic agents such as gemcitabine, capecitabine, floxuridine, ... DG News

Federal Register 2007 - 72 FR 8184 Withdrawal of Approval of 128 …  -  Feb 23, 2007
Codeine Phosphate 15 mg ---------------------------------------------------- -------------------- 86P-0242/ Floxuridine 500 mg/5 mL Quad Pharmaceuticals, ... Pay-Per-View - Federal Register 2007 - Loislaw

Factiva Search  -  Sep 26, 2005
Celator is developing CPX 1, a combination therapy consisting of irinotecan and floxuridine, for the potential treatment ... ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones

Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in …  -  Dec 6, 2008
The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; ... prnewswire.com

Alabama Administrative Code - 540-X-4-.07 Emergency Prescription …  -  Aug 17, 2005
...and Floxuridine (III) Cytarabine (IV) Mercaptopurine (V) Thioguanine (iv) Hormones (I) Androgens I Testolactone (II) Progestins I Megestrol Acetate II. ... Pay-Per-View - Alabama Administrative Code - Loislaw

Celator Pharmaceuticals presents positive results from Phase I study...  -  Jun 5, 2006
CPX-1, a fixed-ratio formulation of irinotecan and floxuridine, was developed using Celator's proprietary CombiPlex technology designed to produce ... Pay-Per-View - Company Reports - Factiva, from Dow Jones

Celator Pharmaceuticals Receives Orphan Drug Designation For …  -  Sep 6, 2008
The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; ... Medical News Today - Medical News Today (press release)

Cancer Therapy; Reports advance knowledge in cancer therapy research  -  Dec 20, 2005
Oncologists in California conducted a study "to determine whether floxuridine (FUDR) can be delivered with low hepatic toxicity" through the PV "as an ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

CPX 1 Celator clinical data (phase I) (solid tumor).  -  Jun 26, 2006
Celator is developing CPX 1, a fixed-ratio combination of irinotecan and floxuridine, as a potential anticancer agent. CPX 1 is being developed using ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones

Alabama Administrative Code - 680-X-2-.26 Emergency Prescription …  -  Aug 17, 2005
Streptozocin (III) Thiotepa (IV) Busulfan (V) Pipobroman (VI) Cisplatin (iii) Antimetabolite (I) Methotrexate (II) Fluorouracil and Floxuridine (III) ... Pay-Per-View - Alabama Administrative Code - Loislaw

Press Release: Celator(R) Pharmaceuticals to Present at 2008 BIO …  -  Jun 16, 2008
The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Celator(R) Pharmaceuticals Announces Positive Phase 2 ...  -  Jun 3, 2008
CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Celator Pharmaceuticals Raises Series C Financing in …  -  Jul 28, 2008
In addition, positive Phase 2 clinical study results were reported for CPX-1 (a liposomal formulation of irinotecan:floxuridine) in patients with advanced ... Pay-Per-View - PR Newswire - HighBeam Research

Georgia Code - 16-13-71. (a) A "dangerous drug" means any drug other ...  -  Aug 4, 2005
...(388.5) Flosequinan; (389) Floxuridine; (389.5) Fluconazole; (390) Flucytosine; (390.5) Fludarabine; (390.7) Fludeoxyglucose; (391) Fludrocortisone; ... Pay-Per-View - Georgia Code - Loislaw

셀레�?�토 'CPX-351' 최�?비율로 전신 약물전달  -  Sep 12, 2008
...올해�?부터 2�? 임�?�?� 시작할 예정�?�며, 그밖�?�?� '�?�리노테칸'(Irinotecan HCI)과 ' 플�?수리딘'(Floxuridine)�?� 최�?비율로 복합한 CPX-1�?� 대장암�? 대해 2�? 임�? ... 디지틀보사

Brand Names/Synonyms:
Floxuridine is also known by the following brand names and/or synonyms5 Fluorodeoxyuridine; 5fdu; Deoxyfluorouridine; FDUR; FUDR; Fdurd; Floxiridina [Inn-Spanish]; Floxuridin; Floxuridine; Floxuridine [Usan:Inn]; Floxuridinum [Inn-Latin]; Fluorodeoxyuridine; Fluoruridine Deoxyribose; HSDB 3227; NSC 27640; NSC-26740; NSC-27640

Drug Category:
Floxuridine is categorized under the following by the FDA: Antivirals; Antimetabolites

Dosage Forms:
POWDER FOR SOLUTION (500mg vial)

Absorption:
Not Available

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
5-fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.